Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow nucleated cells
- Development stage
- Unknown
- Lead developer
- Terumo
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal, Intravenous, Intra-arterial, Parenteral
01
Overview
Autologous bone marrow nucleated cells (BMNCs) are a heterogeneous population of cells harvested from a patient's own bone marrow, typically via aspiration from the iliac crest. This cell population includes hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and various mature leukocytes. The therapeutic application involves concentrating these cells—often using specialized centrifugation systems like the Harvest BMAC or Terumo SmartPRep2—and delivering them to damaged tissues. The mechanism of action is primarily attributed to paracrine effects, where the cells secrete a variety of cytokines, chemokines, and growth factors (such as VEGF and BDNF) that promote angiogenesis, reduce inflammation, and support endogenous tissue repair. BMNCs are being investigated for a wide range of conditions, including cerebral palsy, congestive heart failure, ischemic stroke, and spinal cord injury, with delivery routes ranging from intrathecal and intravenous to direct intramyocardial injection.
- Other names
- autologous bone marrow-derived mononuclear cellsBM-MNCsbone marrow aspirate concentrateBMACautologous concentrated bone marrow nucleated cells
Beyond the preview
Go deeper on autologous bone marrow nucleated cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow nucleated cells.